Cx601 is a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally. Under the terms of the deal, TiGenix will receive an upfront cash payment of €25M, milestones
Under the new multi-year enterprise deal, Medidata Clinical Cloud will be incorporated into all clinical trials across Hanmi’s drug development programs. Hanmi has more than doubled its investment
The designation provides Araim with a seven year marketing exclusivity period against competition, and several incentives such as federal grants, tax credits and a waiver of PDUFA filing
The companies have signed a definitive agreement, which includes an exclusive option for Takeda to acquire Altos starting on the date of the deal and continuing for a
The drug’s second indication in less than a year will let it be used in combination with dexamethasone alone in adults with multiple myeloma who have received at
LEO Pharma will pay AstraZeneca $115m in upfront payment, $1bn in milestones and up to mid-teen tiered percentage royalties on product sales. Tralokinumab is also in phase III
Belkyra, which is made of deoxycholic acid, will be made available under prescription to adults where there is a psychological impact for the patient. When injected into subcutaneous
Firmagon is an antagonist form of androgen deprivation therapy that reversibly binds to the GnRH receptors, inhibiting the production of testosterone immediately. The European Medicines Agency initially approved
Osteogenesis Imperfecta (OI) is a rare, chronic genetic disorder that results in bones that can break easily. The Company intends to initiate a potential registration trial of BPS-804
ICOS is a co-stimulatory receptor that enhances T-cell responses and results in an increased anti-tumour response from the immune system.ICOS is a co-stimulatory receptor that enhances T-cell responses
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.